دورية أكاديمية
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
| العنوان: | MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. |
|---|---|
| المؤلفون: | Hu, Shimin, Xu-Monette, Zijun Y, Tzankov, Alexander, Green, Tina, Wu, Lin, Balasubramanyam, Aarthi, Liu, Wei-min, Visco, Carlo, Li, Yong, Miranda, Roberto N, Montes-Moreno, Santiago, Dybkaer, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L, Hsi, Eric D, Choi, William WL, Zhao, Xiaoying, van Krieken, J Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés JM, Zhou, Fan, Slack, Graham W, Gascoyne, Randy D, Tu, Meifeng, Variakojis, Daina, Chen, Weina, Go, Ronald S, Piris, Miguel A, Møller, Michael B, Medeiros, L Jeffrey, Young, Ken H |
| بيانات النشر: | American Society of Hematology |
| سنة النشر: | 2019 |
| المجموعة: | Duke University Libraries: DukeSpace |
| مصطلحات موضوعية: | B-Lymphocyte Subsets, Humans, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-bcl-2, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Risk Factors, Survival Analysis, Retrospective Studies, Cohort Studies, Lymphocyte Activation, Gene Expression Regulation, Neoplastic, International Cooperation, Adult, Aged, 80 and over, Middle Aged, Female, Male, Lymphoma, Large B-Cell, Diffuse, Antibodies, Monoclonal, Murine-Derived |
| الوصف: | Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein coexpression occurred significantly more commonly in the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2 coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression. DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0006-4971 1528-0020 |
| العلاقة: | Blood; blood-2012-10-460063; https://hdl.handle.net/10161/19329Test |
| الإتاحة: | https://hdl.handle.net/10161/19329Test |
| رقم الانضمام: | edsbas.84223D4E |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|